Please login to the form below
systemic lupus erythematosus
This page shows the latest systemic lupus erythematosus news and features for those working in and with pharma, biotech and healthcare.
Positive results for Biogen’s lupus drug published in NEJM
The New England Journal of Medicine (NEJM) has published positive results from the cutaneous lupus erythematosus (CLE) portion of the two-part phase 2 LILAC study, assessing Biogen’s litifilimab – known ... The company has pushed litifilimab to the
Latest news
-
Phase 3 trial initiated to evaluate AZ's Saphnelo in lupus nephritis
AstraZeneca’s Saphnelo (anifrolumab) has already been approved for the treatment of moderate to severe systemic lupus erythematosus (SLE) in Europe, the US, Japan and Canada. ... Following the approval of Saphnelo as the first new treatment for
-
AZ’s Saphnelo receives EU approval for systemic lupus erythematosus
In Europe, there have been limited treatment options for patients living with systemic lupus erythematosus and many patients face poor outcomes,” he added. ... Mene Pangalos, executive vice president, BioPharmaceuticals R&D, AstraZeneca, said:
-
AstraZeneca’s Saphnelo to be approved in Europe for lupus
The EMA is set to approve the first new treatment for systemic lupus erythematosus in Europe in more than a decade. ... The committee has recommended the monoclonal antibody to the European Medicines Agency (EMA) as an add-on treatment for
-
AstraZeneca signs for-profit agreements for its COVID-19 vaccine
Soriot was keen to mention the “exceptional pipeline delivery” including the launch of Saphnelo (anifrolumab) in the US for systemic lupus erythematosus and Ultomiris (ravulizumab) in the EU for children/adolescents
-
Biogen doses first patient in phase 3 systemic lupus erythematosus study
Biogen has started dosing patients in a late-stage study evaluating its potential systemic lupus erythematosus (SLE) treatment BIIB059. ... systemic and cutaneous lupus,” said Nathalie Franchimont, head of the multiple sclerosis and immunology
More from news
Approximately 4 fully matching, plus 30 partially matching documents found.
Latest Intelligence
-
Should we stop talking about people as patients and start thinking of them as partners? After all, it is their physical and mental health and well-being
15 of those apps focused specifically on systemic lupus erythematosus (lupus) and when assessed against ORCHA’s 350-point checklist, just one app was able to provide evidence of efficacy and ... So what did those with lupus say they needed to help them
-
Rethinking trials: the pros and cons of protocol amendments
A protocol change can work wonders – just ask AstraZeneca. In August, AstraZeneca’s systemic lupus erythematosus candidate anifrolumab achieved the primary efficacy endpoint in an amended trial called Tulip-2. ... Systemic lupus erythematosus is a
-
Pharma deals during September 2012
In a similar vein, Biogen Idec has sold its royalty rights to Benlysta (belimunab) for the treatment of systemic lupus erythematosus, to DRI Capital Managed Fund. ... Royalty monetisation. Benlysta (belimunab) for the treatment of systemic lupus
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
Latest appointments
-
Santhera CEO Klaus Schollmeier joins SuppreMol
This product is SM101, which is being investigated for its use in the treatment of primary immune thrombocytopenia (ITP) and systemic lupus erythematosus (SLE).
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest from PMHub
-
Black community representation in clinical trials
For example, in a Phase III Active Systemic Lupus Erythematosus (SLE) study Sites receiving diversity outreach visits saw a 63% increase in randomised patients than those without.
-
Clinical trials and the diversity principle
Examples abound, but systemic lupus erythematosus (SLE) – a disease for which there has only been one new drug approval since 1955 – is a notable case in point: while Black people account ... COVID has been like a magnifying glass, revealing systemic
-
InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
systemic lupus erythematosus (SLE).
More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Country Manager, Healthcare Communications Agency, Germany
-
Highly competitive salary
- bluebird bio reveals plans to launch two gene therapies
- Sanofi halts recruitment for trials assessing MS treatment
- Eli Lilly to make bebtelovimab commercially available to US states from August
- The patient voice – the value of patient-reported outcomes in HTA
- AbbVie and Sosei Heptares collaborate in new agreement worth up to $1.2bn
- ONS records a continued fall in UK COVID-19 infections
- Powering Rapid Cognitive Analysis with AI
- How the Royal Society’s EiR programme can help to drive UK innovation
- BMS and 2seventy bio announce positive results for multiple myeloma treatment
- Roche and Cend Therapeutics to evaluate pancreatic cancer combination therapy
- Aqilion initiates phase 1 clinical trial for chronic inflammatory diseases
- JCVI publishes statement on London polio vaccination strategy
- Eli Lilly to make bebtelovimab commercially available to US states from August
- Amgen acquires ChemoCentryx in $3.7bn cash deal
- AstraZeneca’s Alexion agrees on $775m settlement with Chugai for Ultomiris
- EMA backs adjuvant use of Roche’s breast cancer ADC Kadcyla
- FDA approves Coherus’ Cimerli as biosimilar interchangeable with Lucentis for all five indications
- Gilead Sciences set to acquire MiroBio in deal worth over $400m
PMHub
Health Unlimited
Health Unlimited is a global health consultancy and communications agency built by specialists with unmatched experience, perspective and expertise. For...
